

Healthcare professional views of implementing remote measurement technology in central nervous system disorders: A qualitative interview study

Jacob Alexander Andrews, Michael P Craven, Jennifer Jamnadas-Khoda, Alexandra R Lang, Richard Morriss, Chris Hollis, The RADAR-CNS Consortium

Submitted to: Journal of Medical Internet Research
on: December 11, 2019

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript	4
Supplementary Files	19
Figures	20
Figure 1.....	21
Figure 2.....	22
Figure 3.....	23
Other materials for editor/reviewers onlies.....	24
Other materials for editor/reviewers only 0	25

Preprint
JMIR Publications

Healthcare professional views of implementing remote measurement technology in central nervous system disorders: A qualitative interview study

Jacob Alexander AndrewsPhD, ; Michael P CravenPhD, ; Jennifer Jamnadas-KhodaMSc, ; Alexandra R LangPhD, ; Richard MorrissMD, FRCPsych, ; Chris HollisPhD, FRCPsych, ; The RADAR-CNS Consortium

Corresponding Author:

Jacob Alexander AndrewsPhD,

Phone: +4401157484218

Email: jacob.andrews@nottingham.ac.uk

Abstract

Background: Remote measurement technologies (RMTs) can be used to collect data on a variety of bio-behavioural variables, which may benefit the care of people with central nervous system disorders. While various studies have explored their potential, prior work has highlighted a knowledge gap concerning healthcare professional's perception of the value of RMTs in clinical practice.

Objective: To understand the perspectives of healthcare professionals on the implementation of RMT in healthcare practice for the care of people with depression, epilepsy or multiple sclerosis.

Methods: Semi-structured interviews were conducted with 26 multidisciplinary primary and secondary care healthcare professionals managing people with epilepsy, depression or multiple sclerosis. Interviews were transcribed verbatim and analysed using thematic analysis.

Results: also indicate points in care pathways at which healthcare staff would most benefit from RMT data, and demonstrate that healthcare professionals are pragmatic about data security risks arising from using patients' RMT data.

Conclusions: RMTs could add value to the system of care for individual patients with central nervous system disorders through providing clinicians with graphic summaries of data in the patient record. Barriers of both technical and human nature should be considered when implementing these technologies, as should the limits to the benefits they can offer.

(JMIR Preprints 11/12/2019:17414)

DOI: <https://doi.org/10.2196/preprints.17414>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

✓ **No, I do not wish to publish my submitted manuscript as a preprint.**


2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in [http](#)

Original Manuscript



Healthcare professional views of implementing remote measurement technology in central nervous system disorders: A qualitative interview study

Authors

J.A. Andrews^{1,2}, M. P. Craven^{1,3}, J. Jamnadas-Khoda^{1,2}, A. Lang⁴, R. Morriss^{1,2,5}, C. Hollis^{1,2,5}, The RADAR-CNS Consortium

Affiliations

1. NIHR MindTech MedTech Co-operative, University of Nottingham, UK
2. University of Nottingham, School of Medicine, Division of Psychiatry and Applied Psychology, UK
3. University of Nottingham, Faculty of Engineering, Bioengineering Research Group, UK
4. University of Nottingham, Faculty of Engineering, Human Factors Research Group, UK
5. NIHR Nottingham Biomedical Research Centre, University of Nottingham, UK

Abstract

Background: Remote measurement technologies (RMTs) can be used to collect data on a variety of bio-behavioural variables, which may benefit the care of people with central nervous system disorders. While various studies have explored their potential, prior work has highlighted a knowledge gap concerning healthcare professional's perception of the value of RMTs in clinical practice.

Objective: To understand the perspectives of healthcare professionals on the implementation of RMT in healthcare practice for the care of people with depression, epilepsy or multiple sclerosis.

Methods: Semi-structured interviews were conducted with 26 multidisciplinary primary and secondary care healthcare professionals managing people with epilepsy, depression or multiple sclerosis. Interviews were transcribed verbatim and analysed using thematic analysis.

Results: Eight main themes emerged from the analysis. These were: potential clinical value of RMT data, when to use RMT in care pathways, healthcare staff roles who may use RMT data, presentation and accessibility of data, obstacles to successful implementation of RMT, limits to the role of RMT, empowering patients, and considerations around alert-based systems.

Conclusions: RMTs could add value to the system of care for individual patients with central nervous system disorders through providing clinicians with graphic summaries of data in the patient record. Barriers of both technical and human nature should be considered when implementing these technologies, as should the limits to the benefits they can offer.

Keywords

Epilepsy; multiple sclerosis; depression; wearables; remote measurement technology; clinicians; healthcare professionals; mobile phones; mhealth; digital health; ehealth

Introduction

In a healthcare context, remote measurement technologies (RMTs) can be used by healthcare professionals (HCPs) and clinical teams to collect data on a patient's health or behaviour, to inform

clinical decision-making. The benefits of RMTs have been explored for treatment/management of patients with cardiac conditions [1-3], early stage dementia [4], neurological disease [5] and attention deficit hyperactivity disorder (ADHD) [6] as well as in behaviour change [7] and monitoring for indicators of sepsis [8] among others.

The European Union H2020 RADAR-CNS project [9] explores the use of RMT in the care of people with epilepsy, depression or multiple sclerosis. These conditions were chosen for this project as exemplars of central nervous system disorders which are under-researched in relation to RMT. As part of this project, RADAR-Base, a cloud-based platform, is being developed to explore the potential to receive data from patients' RMT and to provide this data to HCPs with a view to informing clinical decision-making [10]. The present study is part of this project, aiming to scope and understand the clinical utility of RMT in the care of patients with epilepsy, depression and multiple-sclerosis.

Previous literature has demonstrated the benefits of implementing RMTs in healthcare practice. A 2013 literature review of uses of RMT in cardiology identified a number of studies evidencing reduced hospital visits in terms of both emergency and routine appointments, as well as higher survival rates, in patients who were monitored using RMT [11]. Benefits were also found in patient relations with the care team, quality of life, and compliance with treatments. No quality appraisal was conducted in this narrative review, however.

Some work has challenged these findings, suggesting little or no evidence for an effect of RMT on key outcomes [12, 13]. Other work has highlighted a number of barriers to implementing RMTs in healthcare practice. Erdmier et al. [14] describe a lack of regulatory control over wearables, and also a number of barriers to progress in implementation, including technical capability, erratic user (patient) behaviour and a lack of transparency from manufacturers. A patient and HCP-led priority setting exercise in the field of digital mental health highlighted the need to explore the impact of removing face-to-face human interaction in care pathways for mental health conditions, and also raised issues of safety, effectiveness, evaluation and inequalities [15]. These issues apply equally to the implementation of RMTs.

Authors of prior work in the area of RMTs highlight a need for research to investigate the value to HCPs of implementing RMTs [13]. Davis et al [16] conducted a systematic review of healthcare staff views of utilising RMT in clinical practice and included 15 relevant studies. They concluded that "there is a critical need to engage end-users in the development and implementation of RMT" and highlighted that the evidence base in this area is small. This paper seeks to address these points by exploring HCP perspectives on the implementation of RMTs in three central nervous system disorders.

Methods

Aim

The study aimed to understand the perspectives of HCPs on the implementation of RMT in healthcare practice for the care of people with depression, epilepsy or multiple sclerosis (MS).

Recruitment

We purposively recruited a sample of 26 HCPs, with the intention of covering multiple clinical roles (with representation from medical, nursing and allied health professionals). Participants were all working in the National Health Service (NHS) in England in the care of people with epilepsy, depression, or multiple sclerosis, or a combination of these conditions. Participants were contacted through the professional networks of research team members.

Procedure

A semi-structured interview approach was deployed, with interviews lasting from 16 to 56 minutes

(mean 30 minutes). An interview schedule was used to guide questioning, with ad hoc follow-up questions used to further explore salient points. Participants gave informed consent and were incentivised with a £15 charity donation.

Twenty three interviews were conducted one to one, while one interview was conducted with three participants together. Thirteen of the interviews were conducted by phone, while eleven were conducted in person. All interviews were recorded start to finish using a voice recorder. The study was approved by the University of Nottingham School of Medicine research ethics committee (ref 277-1802).

Analysis

Interviews were transcribed verbatim and analysed using thematic analysis [17]. Data were coded and themed (by JA) using Nvivo 12 (QSR International). Initial codes and themes were discussed within the research team and were iteratively renamed and reformed throughout the analysis process. No new themes emerged when the last interview was coded and so it is considered that the sample reached data saturation.

Results

Participants

Participants were HCPs (medical doctors, nurses, clinical psychologists, physiotherapist and dietitian) from 13 NHS trusts (healthcare organisations) within England. Eight out of 26 participants (31%) were female. Six specialised in the care of people with depression, 12 in epilepsy, six in MS, and two were general practitioners working across all three conditions. Participants included both primary and secondary care clinicians. Thirteen of the 26 interviewees had used RMT with their patients, and 14 of 26 said their patients had brought data to appointments. Healthcare roles of the participants are presented in Table 1, along with their specialism and gender.

Clinical specialism	Depression (n=6)	Epilepsy (n=12)	MS (n=6)	Generalist (n=2)	TOTAL (n=26)
Gender: n female (%)	1 (16.7)	4 (33.3)	2 (33.3)	1 (50)	8 (30.8)
Job role:					
Psychiatrist	4	-	-	-	4
Psychologist	1	-	2	-	3
Neurologist	-	6	3	-	9
Dietician	-	1	-	-	1
Specialist nurse	1	4	-	-	5
Physiotherapist	-	-	1	-	1
General practitioner	-	1	-	2	3

Table 1. Job roles, genders and specialisms of interview participants.

Thematic analysis

Our analysis generated eight main themes, each of which also featured a number of subthemes.

Theme 1: Potential clinical value of remote measurement data

The interviews explored the types of physiological, psychosocial and lifestyle variables that could be targets for measurement using RMTs. HCPs described uses for certain variables they considered to be potentially useful in the care of people with one of the three conditions. Variables considered by participants to hold potential are summarised in table 2.

Condition	Variable
Epilepsy	Activity, anxiety, cognition, diet/food intake ¹ , heart rate ² , mood, quality of life,

	seizures (or proxies thereof), sleep.
Depression	Activity, anxiety, diet/food intake, mood, relapse signatures, sleep, weight.
Multiple Sclerosis	Activity/mobility, anxiety, cognition, fatigue, mood, pain, quality of life, visual acuity.

Notes:

- 1) Opposing views on the value of measuring diet were offered by different participants.
- 2) It was noted that heart rate would be worth measuring in epilepsy only if proven to be a proxy measure of seizures.

Table 2. Target variables considered potentially useful to measure using RMT.

Epilepsy: Participants stated that it would be useful to collect data from RMTs that could indicate the occurrence of a seizure or number of seizures, especially in those who have many. However participants thought that current approaches to seizure detection (e.g. Empatica, Embrace) were limited by lack of sensitivity to detect the full range of seizure types:

“The limitations of this particular device is that it is designed for detecting repetitive movements which is of use for tonic clonic seizures, however, there are different types of seizures which definitely don’t all involve movement but are still epileptic so they wouldn’t be able to detect that [...] It would be ideal to have something where all types of seizures would be recorded.” (P02)

Several types of RMT data were mentioned by participants as possible proxy measures of seizures. These were: skin conductance, heart rate, accelerometry, pressure sensor readings, and electroencephalography (EEG). There were differing views on the usefulness of measuring heart rate and bed pressure as proxy measures for seizures given the possibility of false positive signals (i.e. lack of specificity).

Video and audio might be utilised remotely to assist with diagnosis and seizure identification, particularly through measurement of the sound and duration of a seizure.

“I will sometimes tell people who struggle to video their loved one in a seizure for whatever reason, just to start the video going, put the phone down, and then it will both record the sound, and the duration of the seizure, which are probably the two most useful things we need, outside of seeing one.” (P09)

Depression: Activity data, including movement and GPS (global positioning system), was thought useful in detecting whether a patient was *“leaving the house”* (P21) or *“getting out and about”* (P06), which in turn could be considered a potential *“proxy marker of depression severity”* (P16). This was also thought to have potential to indicate a patient’s global level of functioning. RMT data was also thought to offer a level of objectivity in the measurement of depression which was otherwise lacking. Prospective mood monitoring using an electronic diary, and measurement of sleep using wearables, were also mentioned as potentially helpful in managing depression, where current systems such as Fitbits and mood diary apps could not collate this information together automatically.

MS: Participants saw potential in the use of RMT to measure fatigue, via a self-report app, and also cognition given its association to relapse. However, some considered it difficult to pick one particular aspect of MS to measure using RMT, because the symptoms experienced by patients vary:

“I don’t think you can have a particular tool that you would need to use for everyone. I think it is largely going to be dependent on the symptom profile.” (P20)

Multiple participants mentioned visual acuity as an important indicator of relapse which could be measured using RMT, although they were unsure if technology would be able to measure it when even well trained humans struggled:

“It would have to be really well designed to pick up those intricacies [...] sometimes it is really difficult even for the neurologist to say this person is having a relapse or they are not” (P19)

Theme 2: When to use RMT in the care pathway

Participants described different points in care pathways when data from RMTs could usefully inform the care of their patients. Figures 1 to 3 demonstrate where participants indicated it could be useful to receive data from RMTs. Clinicians indicated that they would like data collected via RMT to be readily accessible in their electronic patient record when patients attended for appointments.

NB. It is acknowledged that not every patient's journey along a care pathway follows the same trajectory. These figures are for illustrative purposes only.

Epilepsy




Figure 1. Participant comments about timing of the use of RMT in the epilepsy care pathway, including monitoring on a yearly basis once stable to allow assessment of follow-up and to create data for future research.




Figure 2. Participant comments about timing of the use of RMT in the depression care pathway, including monitoring during a change in treatment.

Multiple Sclerosis




Figure 3. Participant comments about timing of the use of RMT in the multiple sclerosis care pathway, indicating the benefits of monitoring for a short period of time prior to an appointment.

Theme 3: Healthcare staff roles who may use RMT data

Participants discussed the healthcare staff roles that should be involved in using any data from RMTs. Across all three conditions, participants suggested that primary care was a good place for data to be managed, given the systems available.

“Primary care is certainly quite well set up with systems in place to action on things based through the electronic patient record.” (P06)

In secondary care, specialist nurses were considered to have the closest relationships with patients among members of the care team, and thus were suggested to be the team member most likely to review data from RMTs. For example, in epilepsy:

“If it’s sort of data that is being in some way downloaded in between clinics, then there would certainly be a role for something like an epilepsy nurse to look at that data.” (P09)

Participants considered it important that all clinical, but not administrative, members of a team involved in the treatment of a patient should have access to RMT data when it is collected.

“The discussions we’ve had are about, is it appropriate for admin staff to review that or actually does it have to be a clinician from a risk perspective [...] Your economic arguments come in about experienced clinicians are too expensive but I think making the wrong triage decision is also too expensive.” (P21)

Theme 4: Presentation and accessibility of RMT data

Participants had a variety of views on the best way for data to be presented to them. Particular emphasis was placed on the importance of interoperability and the ability for any data from RMTs to be accessible within an existing electronic patient record (EPR) system rather than requiring the opening of another window or program.

“If [...] you want to have the information available to you at times other than when your patient is there, then it would be good if it could feed directly into your electronic patient record.” (P07)

Across all three conditions, HCPs were keen to have data aggregated in a visual/ graphical format. Some also recalled instances where they had used devices or software which presented information in graphs automatically, and commented that this was useful for the patient as well as for the clinician.

“For most of them [mood-reporting apps] you can do a graph function so they can show you the whole three months, in a fairly small chart, which helps us to think about if there have been any stresses or life events that have changed their mood or whether there’s a pattern to the time of day, and so on.” (P07)

Speed of access to information was also considered to be a priority. Participants spoke of particular situations in which the use of digital records could usefully increase efficiency through time-saving.

“I certainly think if you can access the information quickly then it could be a focus point for the whole consultation and it could speed things up.” (P16)

Uploading data to the EPR was considered preferable to reviewing data that patients brought to the clinic on their mobile phones.

“It could be sent in and loaded up in the patients notes or some other big screen device otherwise you are kind of stuck with little handheld mobiles and it’s not really that helpful.” (P13)

Theme 5: Obstacles to successful implementation of RMTs

Participants mentioned several aspects of the use of RMTs which they considered to be obstacles to their successful use and adoption in practice. These fitted into two broad categories of ‘technical issues’ and ‘human issues’.

The most frequently mentioned technical issue was data accuracy (*“I’m not sure they’re accurate”*, P03). However, participants indicated they would be happy to use devices even where these provided data which were not 100% accurate, so long as the clinician was aware of the margins of error that the data may contain.

“So being as clear as possible what the potential pitfalls might be about all the data that we get back [...] I think as long as you know, kind of where it might go wrong, or how to be careful which bits to not over-interpret, then I think it’s fine” (P09)

There was also concern about the interoperability of any new systems with existing ones, as

clinicians are already required to use several different software packages to manage patients.

“The main trouble currently is a lack of integration” (P01)

Data security was also discussed as an important issue to consider, although participants had differing views on the level of risk that providing data remotely may entail. Some had concerns.

“Who has access to this data? Including if they have it on their phone, what if their phone goes missing, where does this data go? There’s a big big, data protection bit, there’s a big big, patient safety bit.” (P03)

Some advocated taking a pragmatic approach to reduce risk while continuing to use technology where it provided a benefit.

“I think as long as appropriate safeguards are taken then that’s fine, and I think sometimes this can be a barrier, an unnecessary barrier to introducing things that can be helpful.” (P06)

Human issues considered obstacles to the use of RMTs largely focused on two areas: patient anxiety and patient motivation. Participants discussed ways in which the use of RMTs may cause patients anxiety through over-focussing on their symptoms, and how this in turn could be problematic for a health service.

“We have had quite a few patients coming in that have used these monitoring devices and say my heart rate is really fast. For them it’s another layer of education so it actually creates us more work.” (P03)

However, others were less concerned, believing that RMTs would not induce anxiety in people who were not prone to it in the first place or that any anxiety would be manageable.

“We’ve always found ways to react to that anxiety, this is just what it looks like in the current generation.” (P21)

Participants suggested that patients with depression would have less motivation to engage with RMTs as a result of their condition.

“A lot of our patients may, especially if they’re more severely depressed, not be very motivated to interact with the app” (P16)

However, the use of RMTs to generate more objective evidence of a patient’s health state was considered by some to be useful in motivating engagement with their care.

“So if you do your usual interview and you’ve got objective evidence to say, I think your depression is coming back or you haven’t been exercising enough or you have way more seizures than you think, then of course, that might help motivating them to do certain things.” (P22)

Theme 6: Limits to the role of RMT

Several of our participants mentioned elements of care in their specialism which, in their view, should not be replaced by an RMT-enabled approach. In MS, the importance of face to face appointments was highlighted as essential for picking up subtle signs of worsening condition.

“You really need to be physically examining the patient as well as hearing their perspective because there’s subtle deficits that you can pick up on at examination that people won’t notice day to day [...] you can pick up things like subtle signs like nystagmus, or problems with the balance or things like that, that people often won’t notice” (P01)

In epilepsy too, HCPs reiterated the importance of seeing their patients face to face.

“If their seizure frequency has increased you’re there thinking I probably need to see you, what else is going on? Have they got a cold, a water infection? Is there something else going on in their life? Are they not taking their tablets? Sometimes some of those conversations need to be had.” (P03)

A general practitioner mentioned the relational side of their work as important in the care of people with depression.

“The relationship element of it is very important, and obviously in primary care a lot of what I’m thinking is around depression [...] the human to human contact with someone who’s

struggling with mood, and the fact that you've got someone who can be empathic and rapport rather than just crunching data" (P06)

Theme 7: Empowering patients

HCPs believed that RMT may benefit patients because it might empower them to take a leading role in their care. Some clinicians thought that patients should lead the use of technology, and therefore have more control over their own care.

"The way I see it is it's more about the patient using the data for themselves, the clinician is almost the passive recipient of the data who is working with the patient to try and interpret it and help them develop techniques to use the data themselves." (P07)

HCPs also spoke of how patients could be given full control of their own data collected using RMTs, and allow that data to be shared with a chosen clinician when they deemed it necessary.

"Within the patient held database, [...] presumably a sort of secure log in, and that is, it's patient-controlled [...] and they could give out the ability to share." (P15)

Participants provided examples of how a patient could be empowered through the use of RMT, by determining when to arrange an appointment based on the outputs from the technology.

"Through prospective mood monitoring you could capture periods where there had been a persistent lowering of mood over two weeks or more with associated other features or even shorter periods than that, that you'd agreed as part of a relapse signature. What people could do in those instances is potentially bring appointments forward." (P13)

However, in the case of depression, participants saw difficulties with patient motivation and thus thought it unlikely that patients would be able to take control of their own care.

"[That] involves them taking a lot of responsibility for their own healthcare and I guess that may work better in some conditions, more than depression." (P16)

For some, it was a case of providing care on an individual basis.

"I would tailor it to what they wanted, so you will have those who are very tech savvy who don't have any time and think this will really suit me, others are very much I really want to see you doctor [...] the key is to listen to them and individualise care rather than doing tick box medicine which we sometimes do." (P03)

Theme 8: Alert-based systems

There was debate across all three conditions in the interviews about the potential to use RMT to alert clinicians when a monitoring variable fell outside normative parameters, for example if seizures increased in severity or frequency, if mood or activity were found to be particularly low, or if fatigue increased. The majority of participants considered such a system to be beneficial, so that interventions could be put in place as soon as possible.

"It would be a system that had parameters set and triggered active alerts when those parameters were exceeded, I think would be the only way that I could see a lot of our consultant body engaging in it." (P01)

However, a small number thought such a system would be problematic, principally because alerts may create excessive demand for immediate processing, interpretation and/or response (for example outside of normal working hours) and there would not be enough healthcare staff available to respond to the alerts produced.

"Outside of fixed appointments the question would be who would actually have time and headspace to actually look at what was being flagged up. You would need to really carefully think about the staffing in the NHS and mental health services." (P13)

HCPs also perceived there to be a risk that alerts would go unnoticed in the system (P03: "My worry is this data arrives and nobody looks at it for weeks, it's sitting somewhere in the ether"). Several participants suggested that it would be more useful if the technology alerted the patient to take action through their regular treatment pathways, rather than putting the onus on the clinician.

“I would want it to prompt the patient to make contact with me.” (P14)

Some saw a need for further research to determine the benefits of an alert-based system.

“Unless you could do a good study and demonstrate that sending me alerts from an automated app would be helpful, then I would just want information that I could look back on when I next met with a patient face to face” (P14)

Discussion

Principal findings

Eight themes emerged from the analysis of our interviews. The first theme covered the potential clinical value of remote measurement data. Where RMTs are currently used in healthcare practice, HCPs find them to be largely inaccurate, particularly in the case of epilepsy, though efforts to develop more effective ways of monitoring epilepsy are welcomed. Participants were optimistic about the future use of activity data to monitor symptoms of depression, and considered that using RMT to collect measures of fatigue and cognition in people with MS would be useful.

In Theme 2, key points in care pathways for the three conditions were identified as times where RMT data could provide most value. These included monitoring a short period of time prior to an appointment (MS), monitoring during a change in treatment (epilepsy), and monitoring on a regular basis once a patient was in a stable condition, to allow assessment of follow-up and to create data for future research (depression, epilepsy and MS).

The third theme considered staff roles in the management of RMT use by patients. Participants suggested all staff involved in a patient's care should have easy access to data generated by RMTs via the patient record. Participants also made it clear that triage using data from RMTs should be conducted by qualified HCPs rather than by administration staff. Primary care staff, and specialist nurses in secondary care, were thought to be well placed to manage incoming data from patients.

With regard to presentation of data, in Theme 4, HCPs described ease and speed of access to RMT data to be important for their successful use, and emphasised the importance of interoperability with the patient record. Presentation of data in graphs was mentioned as helpful for interpretation.

Theme 5 discussed obstacles to the successful use of RMTs, and these included both 'technical issues' such as data accuracy and data security (where views differed on the risks involved), and 'human issues', such as anxiety created by monitoring (although not all participants agreed that this was an issue).

In theme 6 on the limits of RMT benefit, participants emphasised that RMT would never completely replace face to face appointments, particularly in depression where relationship was considered important.

The seventh theme concerned patient empowerment. HCPs expressed the value in giving patients access to their own data, enabling them to take an active role in their own care, for example by advancing appointments where RMT data indicated it was necessary. However, there was some concern about depression patients having the motivation to take responsibility for their own care.

Theme 8 related to alert-based systems. Participants debated the value of such systems, and highlighted requirements for their successful use. Some thought alerts should be used to invite the patient to take action rather than alerting a clinician, due to workload concerns. The need for further research to determine the benefits of alert-based systems was also highlighted.

Comparison with prior work

While prior work exploring RMT in healthcare has principally identified benefits and barriers to its implementation (e.g. [11] [14]), the present study has investigated HCPs' perceptions of the clinical value of implementing RMTs, helping to address a knowledge gap identified by Vegesna et al. [13] and Davis et al [16].

The themes emerging in this study add to findings from prior work in this area. Our findings support the work of Bruno et al [18], who highlight that healthcare professionals may view the management of data from digital devices as a burden. Goodrich and colleagues, among others, have highlighted the importance of interoperability and a preference for data from mobile technologies to be automatically integrated into clinical records [19], similar to the views of our participants. Clinician concern about the need to respond to alert-based systems has also been raised previously [16, 20].

Prior work has also emphasised the importance of face-to-face contact in the context of digital technology and mental health care [21]. A priority setting exercise for digital mental health [15] identified a need to explore the impact of removing such interactions from care pathways. Our data has shown that HCPs view face-to-face appointments as essential in the care of patients with these three conditions, even where RMT could provide them with detailed recent data on a patient's status. Our data show too that HCPs imagine patients could be empowered to determine their own need for a clinical appointment based on data from RMT, helping to address questions around impact of technology on access to services which has also been identified as a research priority [15].

Davis' Technology Acceptance Model [22] describes perceived usefulness and perceived ease of use as key mediators to the successful uptake of a new technology. Our analysis highlights ways in which clinicians perceive RMT data could be useful (theme 1), as well as where there are limits or obstacles to this usefulness (themes 5 and 6). We have also identified how speed and ease of access to data are desirable for HCPs (theme 4), evidencing how perceived ease of use is applicable to this area. The analysis also raises the tailoring of care for patients using RMT (theme 7), where it was discussed that patients' perception of RMT should be that it is both useful and easy to use in order to motivate continued use.

Beyond the findings presented in previous work, our findings specify the types of RMT data clinicians would value in the management of epilepsy, depression and MS, as well as the points in patient care at which these data would be of most use and the healthcare roles that would be best placed to manage this data.

Implications for researchers and developers

Findings from these themes will help to inform the development of the RADAR-CNS approach in the application of RMT for better care for epilepsy, MS and depression. Researchers and companies developing monitoring technologies should ensure the boundaries of accuracy of any new solution are well defined, such that clinicians can understand the level of confidence they should place in readings from such devices. Since HCPs believe patients may benefit from the option to move/advance appointments based on their data, it would also be worthwhile for any mobile health solutions to link with appointment planning services, so that these can be easily accessed. In the United Kingdom, the NHS app is an example of such a system.

Strengths and limitations

This study has a number of strengths. We recruited a multidisciplinary group of HCPs working in a variety of clinical staff roles in primary and secondary care. Therefore the use of RMTs was considered from multiple perspectives. The study was limited in its consideration of only three specific central nervous system disorders in one national health care system. However, the analysis has considered how insights gained from staff working in these three conditions might generalise, and has permitted a deeper analysis of the three conditions mentioned. The ratio of male to female participants was high, with only eight out of 26 participants being female. Epilepsy staff were over-represented in comparison with depression and multiple sclerosis due to the convenience sampling method. However, staff were represented across most roles in the care team for each of the three conditions represented, with the exception of MS, where an MS nurse could not be recruited in the time available.

Future directions

While we have focussed our consideration of the use of patient RMT data on an individual basis, further work could usefully explore the use of combined RMT data from groups of patients to assess risk or identify trends. The 2019 Topol Review highlighted the potential of integrating predictive analytics into diagnosis and care pathways [23], and data from RMTs could feed into these approaches.

Work should also explore the views of health service managers, commissioners and public health representatives to understand the value that implementation of RMTs could provide from a healthcare system payer and management perspective, for example in its potential to increase efficiencies and improve outcomes for different patient populations.

Given participants' views on the importance of nurses' roles in the management of patients' use of RMT, it would be useful to conduct further research to better understand nurses' views on subsuming associated responsibilities into their roles. While some work has explored nurses' views on their roles in use of technology in intensive care situations [24] and telehealth for diabetes [25], to our knowledge none has yet explored views specifically relating to RMT in CNS disorders.

Further work should also be completed to understand how RMTs might best facilitate increased patient autonomy (as advocated in the NHS Long Term Plan [26]), and situations where this may be less appropriate or successful. The RADAR-MDD study is recruiting 600 people with major depressive disorder to use RMTs over a period two years, and this study may shed light in this area [27].

Conclusions

This paper has explored the views of healthcare professionals on implementing remote measurement technology in the management of central nervous system disorders, specifically in epilepsy, MS and depression. The results have detailed:

- target physiological variables for measurement that clinicians believe would be useful
- points in care pathways at which clinicians perceive benefit to patients using RMTs
- roles of healthcare staff best placed to manage incoming data
- HCPs' preferred presentation of data
- obstacles to the successful implementation of RMTs
- limits to the benefits that RMT can provide
- ways in which patients may be empowered through use of RMTs
- considerations around alert-based systems.

Our findings show the importance of early engagement and co-design with healthcare professionals when considering user requirements and potential use cases before implementing RMT in clinical care pathways. HCPs believe that RMT data can add value to the care of patients with these three conditions, but are not sufficient for decisions about care to be made exclusively on the basis of these data. We have demonstrated that clinicians are pragmatic about the data security risks of using RMT data with patients. Further research is required to establish how RMT data could be used on a population level to benefit patients with central nervous system disorders.

Acknowledgement

The Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS) project (www.radar-cns.org) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and European Federation of

Pharmaceutical Industries and Associations (EFPIA) (www.imi.europa.eu). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body have not been involved in the design of the study, the collection or analysis of data, or the interpretation of data.

This research was supported by the National Institute for Health Research: NIHR MindTech MedTech Co-operative; NIHR Nottingham Biomedical Research Centre; and NIHR Applied Research Collaboration East Midlands. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

References


1. Guedon-Moreau, L., P. Mabo, and S. Kacet, *Current clinical evidence for remote patient management*. *Europace*, 2013. **15 Suppl 1**: p. i6-i10.
2. Martirosyan, M., et al., *Remote monitoring of heart failure: benefits for therapeutic decision making*. *Expert Rev Cardiovasc Ther*, 2017. **15(7)**: p. 503-515.
3. Varma, N. and R.P. Ricci, *Impact of Remote Monitoring on Clinical Outcomes*. *J Cardiovasc Electrophysiol*, 2015. **26(12)**: p. 1388-95.
4. Holbø, K., S. Bøthun, and Y. Dahl, *Safe walking technology for people with dementia: what do they want?*, in *Proceedings of the 15th International ACM SIGACCESS Conference on Computers and Accessibility*. 2013, ACM: Bellevue, Washington. p. 1-8.
5. Block, V.A., et al., *Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review*. *PLoS One*, 2016. **11(4)**: p. e0154335.
6. Simons, L., et al., *Developing mHealth Remote Monitoring Technology for Attention Deficit Hyperactivity Disorder: A Qualitative Study Eliciting User Priorities and Needs*. *JMIR Mhealth Uhealth*, 2016. **4(1)**: p. e31.
7. Kurti, A.N., et al., *A Review of the Literature on Remote Monitoring Technology in Incentive-Based Interventions for Health-Related Behavior Change*. *Transl Issues Psychol Sci*, 2016. **2(2)**: p. 128-152.
8. Bui, T., et al., *Remote Patient Monitoring for Improving Outpatient Care of Patients at Risk for Sepsis*. 2016 IEEE Systems and Information Engineering Design Symposium (SIEDS), 2016: p. 136-141.
9. Glauser, T., et al., *Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society*. *Epilepsy Currents*, 2016. **16(1)**: p. 48-61.
10. Ranjan, Y., et al., *RADAR-Base: Open Source Mobile Health Platform for Collecting, Monitoring, and Analyzing Data Using Sensors, Wearables, and Mobile Devices*. *JMIR Mhealth Uhealth*, 2019. **7(8)**: p. e11734.
11. Chronaki, C.E. and P. Vardas, *Remote monitoring costs, benefits, and reimbursement: a European perspective*. *Europace*, 2013. **15 Suppl 1**: p. i59-i64.
12. Noah, B., et al., *Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials*. *NPJ Digit Med*, 2018. **1**: p. 20172.
13. Vegesna, A., et al., *Remote Patient Monitoring via Non-Invasive Digital Technologies: A Systematic Review*. *Telemed J E Health*, 2017. **23(1)**: p. 3-17.
14. Erdmier, C., J. Hatcher, and M. Lee, *Wearable device implications in the healthcare industry*. *J Med Eng Technol*, 2016. **40(4)**: p. 141-8.
15. Hollis, C., et al., *Identifying research priorities for digital technology in mental health care: results of the James Lind Alliance Priority Setting Partnership*. *Lancet Psychiatry*, 2018. **5(10)**: p. 845-854.
16. Davis, M.M., et al., *A systematic review of clinician and staff views on the acceptability of*

- incorporating remote monitoring technology into primary care.* Telemed J E Health, 2014. **20**(5): p. 428-38.
17. Braun, V. and V. Clarke, *Using thematic analysis in psychology.* Qualitative Research in Psychology, 2006. **3**(2): p. 77-101.
 18. Bruno, E., et al., *Wearable technology in epilepsy: The views of patients, caregivers, and healthcare professionals.* Epilepsy Behav, 2018. **85**: p. 141-149.
 19. Goodrich, D.E., et al., *Integrating an internet-mediated walking program into family medicine clinical practice: a pilot feasibility study.* BMC Med Inform Decis Mak, 2011. **11**: p. 47.
 20. Lamothe, L., et al., *Impacts of telehomecare on patients, providers, and organizations.* Telemed J E Health, 2006. **12**(3): p. 363-9.
 21. Brooks, E., C. Turvey, and E.F. Augusterfer, *Provider barriers to telemental health: obstacles overcome, obstacles remaining.* Telemed J E Health, 2013. **19**(6): p. 433-7.
 22. Davis, F.D., *Perceived Usefulness, Perceived Ease of Use, and User Acceptance of Information Technology.* Mis Quarterly, 1989. **13**(3): p. 319-340.
 23. HEE, *The Topol Review. Health Education England NHS.* 2019, Health Education England NHS.
 24. Alasad, J., *Managing technology in the intensive care unit: the nurses' experience.* International Journal of Nursing Studies, 2002. **39**(4): p. 407-413.
 25. Starren, J., et al., *The role of nurses in installing telehealth technology in the home.* Cin-Computers Informatics Nursing, 2005. **23**(4): p. 181-189.
 26. NHS. *NHS Long Term Plan 2019*; Available from: <https://www.longtermplan.nhs.uk/>.
 27. Matcham, F., et al., *Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol.* BMC Psychiatry, 2019. **19**(1): p. 72.


Abbreviations

ADHD	Attention deficit hyperactivity disorder
CNS	Central nervous system
EEG	Electroencephalography
EFPIA	European Federation of Pharmaceutical Industries and Associations
EPR	Electronic patient record
GPS	Global positioning system
HCP	Healthcare practitioner
MS	Multiple sclerosis
NHS	National Health Service
NIHR	National Institute for Health Research
RADAR-CNS	Remote Assessment of Disease and Relapse – Central nervous system
RADAR-MDD	Remote Assessment of Disease and Relapse – Major depressive disorder
RMT	Remote measurement technology


Supplementary Files




Figures




Participant comments about timing of the use of RMT in the epilepsy care pathway, including monitoring on a yearly basis once stable to allow assessment of follow-up and to create data for future research.




Participant comments about timing of the use of RMT in the depression care pathway, including monitoring during a change in treatment.



Participant comments about timing of the use of RMT in the multiple sclerosis care pathway, indicating the benefits of monitoring for a short period of time prior to an appointment.



Other materials for editor/reviewers onlies



Revised manuscript after review with tracked changes to make changes clear.
URL: <https://asset.jmir.pub/assets/0c1265fe1581e29cb2c6a2578a2bae83.docx>

